KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Short term Debt (2018 - 2020)

Emergent BioSolutions' Short term Debt history spans 7 years, with the latest figure at $22.3 million for Q2 2020.

  • For Q2 2020, Short term Debt fell 59.16% year-over-year to $22.3 million; the TTM value through Jun 2020 reached $22.3 million, down 59.16%, while the annual FY2019 figure was $3.2 million, 42.86% down from the prior year.
  • Short term Debt reached $22.3 million in Q2 2020 per EBS's latest filing, up from $3.2 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $54.6 million in Q2 2019 to a low of $3.2 million in Q4 2019.
  • Average Short term Debt over 3 years is $17.6 million, with a median of $10.1 million recorded in 2019.
  • Peak YoY movement for Short term Debt: tumbled 42.86% in 2019, then plummeted 59.16% in 2020.
  • A 3-year view of Short term Debt shows it stood at $5.6 million in 2018, then crashed by 42.86% to $3.2 million in 2019, then skyrocketed by 596.88% to $22.3 million in 2020.
  • Per Business Quant, the three most recent readings for EBS's Short term Debt are $22.3 million (Q2 2020), $3.2 million (Q4 2019), and $10.1 million (Q3 2019).